Authors' objectives: Lymphoma is a cancer of the lymphatic system, which is part of the immune system. It contains cells called lymphocytes that fight infections. Diffuse large B cell lymphoma is the most common type of non-Hodgkin's lymphoma. It can occur at any age but is more common in those over 65 years of age. Nivolumab is a new antibody drug for the treatment of diffuse large B cell lymphoma and is delivered straight into the bloodstream via a drip. Some studies have suggested that this drug may be helpful for people with diffuse large B cell lymphoma whose disease has returned after the first treatment did not work. Another, larger study is now running and is aiming to find out how well nivolumab works and that it is safe to use. If nivolumab is licenced for use in the UK, it could be a new treatment option for diffuse large B cell lymphoma that may improve survival when current treatments have stopped working.

Project Status: Completed

Year Published: 2015

URL for published report: http://www.hsric.nihr.ac.uk/topics/nivolumab-opdivo-for-diffuse-large-b-cell-lymphoma-second-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)